Anti-CD9 [P1/33/2] recombinant antibody
Invented at University of Oxford
- Datasheet
- References (3)
- Inventor Info
Info
| Catalogue Number | 154820 |
| Antigen/Gene or Protein Targets | CD9 |
| Synonyms | CD9 Molecule; Cell Growth-Inhibiting Gene 2 Protein; Motility Related Protein-1; Leukocyte Antigen MIC3; CD9 Antigen (P24); Tetraspanin-29; 5H9 Antigen; TSPAN29; MRP-1 |
| Reactivity | Human |
| Relevance | CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for functional studies on platelets |
| Host | Mouse |
| Immunogen | Acute lymphoblastic leukaemia cells |
| Subclass | IgG1 |
| Research Area | Cancer, Cardiovascular, Cell Type or Organelle Marker, Developmental Biology, Immunology, Stem Cell Biology |
References: 3 entries
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.
Jennings et al. 1993. CD9 cluster workshop report: cell surface binding and functional analysis. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51
Taghizadeh et al. 2010. PLoS One. 5(12):e15183. PMID: 21203549.
Add a reference
References: 3 entries
CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.
Jennings et al. 1993. CD9 cluster workshop report: cell surface binding and functional analysis. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51
Taghizadeh et al. 2010. PLoS One. 5(12):e15183. PMID: 21203549.
Add a reference
